Enrollment
Treatment-Resistant Heart Failure (HF) and Peritoneal Ultrafiltration (PUF): A Randomized Prospective Trial of Standard Care Versus Standard Care With Peritoneal Ultrafiltration in Patients With Treatment-Resistant Severe Heart Failure
Sponsor study identifier
interventional
12
4 countries
11
Study Start
August 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
April 2008
Actual (reported)Study Completion
April 2008
Actual (reported)The objective of the study is to determine if the addition of peritoneal ultrafiltration to standard therapy in treatment-resistant severe heart failure patients will improve fluid balance and functional capacity such that they will spend less time in the hospital and have an improved ambulatory quality of life in comparison to patients who remain on standard therapy alone.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2006
Date type not reportedThis date has not been verified as actual or estimated.
August 23, 2006
Actual (reported)August 25, 2006
Actual (reported)April 2008
Actual (reported)April 2008
Actual (reported)June 17, 2009
Actual (reported)All-cause Hospitalization (Unadjusted)
All-cause hospitalization was defined as (1) hospitalization for any cause of any duration or (2)any ER visit or any clinic visit specifically for congestive heart failure requiring intravenous administration of an inotrope, vasodilator or diuretic.
6 to 24 months
peritoneal dialysis
Periotneal Dialysis
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
San Jose, California, United States
Torrance, California, United States
Denver, Colorado, United States
Evanston, Illinois, United States
Winston-Salem, North Carolina, United States
Melbourne, Victoria, Australia
Leuven, Belgium
The number of subjects enrolled \& duration of therapy were insufficient to complete the planned efficacy analyses \& to draw any conclusion regarding all-cause hospitalization rates in both intervention and standard therapy arms.
12 participants (actual enrollment reported by the registry).
First Submitted
August 23, 2006
First Posted
August 25, 2006
Study Start
August 2006
Date type not reportedThis date has not been verified as actual or estimated.
Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
Contact the study team to confirm eligibility.
Liège, Belgium
Roeselare, Belgium
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Primary Completion
April 2008
Actual (reported)Study Completion
April 2008
Actual (reported)Last Updated
July 15, 2025
Results First Posted
June 17, 2009
Record last verified: 2025-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: